Thus, these data suggest that such an approach could lead to a novel therapeutic strategy that should be widely applicable given the high prevalence for p53 mutations in SCCHN (CATG report ca. 80% in non-HPV disease [4]). The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.